摘要:
The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 antagonist for the manufacture of a medicament for oral administration for the treatment or prevention of movement disorders, methods of treatment using such a NK-1 receptor antagonist and pharmaceutical compositions comprising it.
摘要:
The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of stress disorders without concomitant therapy with other anti-stress agents, methods of treatment using such a NK-1 receptor antagonist and pharmaceutical compositions comprising it.
摘要:
The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of major depressive disorder with anxiety without concomitant therapy with other anti-depressant or anti-anxiety agents, methods of treatment using such a NK-1 receptor antagonist and pharmaceutical compositions comprising the same.
摘要:
The present invention provides compounds of formula (I), wherein R1 is phenyl or a 5- or 6-membered aromatic heterocyclic group containing 1, 2, 3 or 4 heteroatoms, selected from nitrogen, oxygen and sulphur, which aryl or heteroaryl group is optionally substituted; R2 is hydrogen, halogen, C¿1-6?alkyl, C1-6alkoxy, CF3, OCF3, NO2, CN, SR?a, SORa, SO¿2Ra, CO2R?a, CONRaRb, C¿2-6alkenyl, C2-6alkynyl or C1-4alkyl substituted by C1-4alkoxy, where R?a and Rb¿ each independently represent hydrogen or C¿1-4?alkyl; R?4, R5, R6, R9a and R9b¿, A, X, and Y are as defined in the specification; the dotted line is an optional double bond; Q1 is oxygen, sulphur or -NH-; Q2 is -N=, -NH-, -CH= or -CH¿2?-; and m is zero or 1; and pharmaceutically acceptable salts and prodrugs thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia.
摘要:
The present invention relates to compounds of formula (I) wherein n is 1, 2 or 3 and where any carbon atom of (CH2)n may be substituted by R4 and/or R5; X represents O or S; R1 represents (CH¿2?)qphenyl, wherein q is 0, 1, 2 or 3, which may be optionally substituted in the phenyl ring; R?2¿ represents aryl selected from phenyl and naphthyl; heteroaryl selected from indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl and quinolyl; benzhydryl; or benzyl; wherein each aryl or heteroaryl moiety may be substituted; R?4 and R5¿ each independently represent H, halo, C¿1-6?alkyl, oxo, CO2R?a¿ or CONRaRb; R6 represents H or C¿1-6?alkyl; R?7¿ represents trifluoromethyl, C¿2-6?alkenyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, (CH2)pNR?9R10, CO¿2R?16, CONR9R10, (CH¿2)pCO2R16, (CH2)pCONR?9R10, (CH¿2)pNR?9COR16, (CH¿2)pNHSO2R11, (CH2)pOR16, (CH2)pOC(O)R9 or (CH¿2?)pOC1-4alkylCOR?17¿ or C¿1-6?alkyl substituted by a hydroxy group; R?8¿ represents H, CORa, CO2Ra, COCONRaRb, COCO¿2R?a, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, C1-6alkyl optionally substituted by a group selected from (CO2R?a, CONRaRb¿, hydroxy, cyano, COR?a, NRaRb¿, C(NOH)NRaRb, CONHphenyl(C¿1-4?alkyl), COCO2R?a¿, CONHNRaRb, C(S)NR?aRb, CONRaC¿1-6alkylR?12, CONR13C¿2-6alkynyl, CONR13C2-6alkenyl, COCONR?aRb, CONRaC(NRb)NRaRb, CONRa¿heteroaryl, and optionally substituted phenyl or C¿1-6?alkyl, optionally substituted by oxo, substituted by an optionally substituted aromatic heterocycle; R?a and Rb¿ each independently represent H, C¿1-6?alkyl, trifluoromethyl or phenyl optionally substituted by C1-6alkyl, halo or trifluoromethyl. The compounds are of particular use in the treatment of pain, inflammation, migraine and emesis.
摘要:
The present invention relates to compounds of formula (I), wherein R1 is hydrogen, halogen, C¿1-6¿ alkyl, C¿1-6? alkoxy, CF3, NO2, CN, SR?a, SORa, SO¿2Ra, CO2R?a, CONRaRb, C¿2-6 alkenyl, C2-6 alkynyl or C1-4 alkyl substituted by C1-4 alkoxy, where R?a and Rb¿ are hydrogen or C¿1-4? alkyl; R?2¿ is hydrogen, halogen, C¿1-6? alkyl, C1-6 alkoxy substituted by C1-4 alkoxy or CF3; R?3¿ is hydrogen, halogen or CF¿3; R?4 is selected from the definitions of R1; R5 is selected from the definitions of R2; R6 is a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =O, =S or a C¿1-4? alkyl group, and optionally substituted by an aminoalkyl group; R?9a and R9b¿ are hydrogen or C¿1-4? alkyl, or R?9a and R9b¿ are joined to form a C¿5-7? ring; X is C1-4 alkylene optionally substituted by oxo; and Y is a C1-4 alkyl group optionally substituted by hydroxyl; with the proviso that if Y is C1-4 alkyl, R?6¿ is substituted at least by an aminoalkyl group; and pharmaceutically acceptable salts and prodrugs thereof. The compounds are of particular use in the treatment of pain, inflammation, migraine and emesis.
摘要:
Compounds of formula (I), and salts and prodrugs thereof wherein n is 1, 2 or 3; X represents O or S; R1 represents optionally substituted phenyl; R2 represents aryl, heteroaryl, benzhydryl, or benzyl; R?4 and R5¿ each independently represent H, halo, CH¿2OR?9, C1-6alkyl, oxo, CO2R10 or CONR?10R11; R8¿ represents H, COR9, CO2R10 or optionally substituted C¿1-6?alkyl; R?9¿ represents H, C¿1-6?alkyl or phenyl; and R?10 and R11¿ each independently represent H or C¿1-6?alkyl; are tachykinin antagonists. They and compositions thereof are useful in medicine.
摘要:
The present invention relates to compounds of formula (I), wherein R1 represents halogen, hydroxy, C¿1-6?alkyl group optionally substituted by one to three fluorine atoms, C1-6alkoxy group optionally substituted by one to three fluorine atoms, or C1-6alkylthio optionally substituted by one to three fluorine atoms; R?2¿ represents hydrogen, halogen, C¿1-6?alkyl or C1-6alkoxy; or when R?2¿ is adjacent to R1, they may be joined together such that there is formed a 5- or 6-membered saturated or unsaturated ring containing one or two oxygen atoms; R3 represents an optionally substituted 5- or 6-membered aromatic heterocyclic group containing 1, 2, 3 or 4 heteroatoms, selected from nitrogen, oxygen and sulphur; R?4, R5, R9 and R10¿ are a variety of substituents; R6 represents hydrogen, CORa, CO2Ra, COCONRaRb, COCO¿2R?a, C1-6alkyl optionally substituted by a group selected from (CO2R?a, CONRaRb¿, hydroxy, CN, COR?a, NRaRb¿, C(NOH)NRaRb, CONHphenyl(C¿1-4?alkyl), COCO2R?a¿, CONHNRaRb, C(S)NR?aRb, CONRaC¿1-6alkylR?12, CONR13C¿2-6alkenyl, CONR13C2-6alkynyl, COCONR?aRb, CONRaC(NRb)NRaRb, CONRa¿heteroaryl, and optionally substituted phenyl) or -CH¿2?C CCH2NR?7R8¿ or C¿1-6?alkyl, optionally substituted by oxo, substituted by an optionally substituted 5-membered or 6-membered heterocyclic ring containing 1, 2 or 3 nitrogen atoms; m is 0-3 and n is 0-3, with the proviso that the sum total of m+n is 2 or 3; p is zero or 1; q is 1 or 2; and when m is 1 and n is 1 or 2, the broken line represents an optional double bond; or a pharmaceutically acceptable salt thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia.
摘要:
The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 antagonist for the manufacture of a medicament for oral administration for the treatment or prevention of movement disorders, methods of treatment using such a NK-1 receptor antagonist and pharmaceutical compositions comprising it.
摘要:
The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of bipolar disorder without concomitant therapy with other antidepressant or anti-anxiety agents, methods of treatment using such an NK-1 receptor antagonist and pharmaceutical compositions comprising the same.